SESSION TITLE: Advances in Cardiac Disease
SESSION TYPE: Original Investigation Slide
PRESENTED ON: Monday, October 26, 2015 at 04:30 PM - 05:30 PM
PURPOSE: Pentraxin-3 (PTX3) is a member of pentraxin superfamily that is structurally and functionally similar to C- reactive protein. PTX3 is suspected to be a specific marker of vascular inflammation. It is produced in response to proinflammatory cytokines (Interleukin 1 and tumor necrosis factor) by cells in atherosclerotic lesions including smooth muscle cells, vascular endothelial cells and macrophages. It is suggested that PTX3 may precisely reflect the inflammatory status of the vascular wall. The association between PTX3 and coronary artery disease (CAD) remains obscure. We conducted a meta-analysis to evaluate the relationship between serum PTX3 levels and coronary artery disease (CAD).
METHODS: We searched MEDLINE, CINHAL and COCHRANE databases for studies reporting serum PTX3 levels in the CAD and non-CAD study population. We included case controls, cohort and cross-sectional studies. We calculated the weighted standardized mean difference (SMD) in serum PTX3 levels between the CAD and control groups
RESULTS: Our search strategy yielded 177 articles and we included 17 studies enrolling 5550 participants. The median age of the CAD group was 65 yrs. (IQR 54.8 - 67.4) compared to 58.5 yrs. (IQR 49 - 64) in the control group. The median body mass index of the CAD group was 25.9 kg/m2 (IQR 25 - 27.4) compared to 26.9 kg/m2 (IQR 24.5 - 27.2) in control group. The median percentage of female population in the CAD group was 35.4% (IQR 18.4 - 40.7) compared to 40.8% (IQR 31.7 - 51.3) in the control group. The unweighted median serum PTX3 levels in the CAD group were 3 ng/ml (IQR 1.7 - 4.1) compared to 1.9 ng/ml (IQR 1 - 2.9) in the control group. The SMD of PTX3 level was 0.959 (95% CI 0.646 - 1.272) p<0.001 comparing those in the CAD group and control group.
CONCLUSIONS: Elevated serum PTX3 levels are significantly associated with CAD. However further studies are required to test this association after adjusting for traditional risk factors.
CLINICAL IMPLICATIONS: PTX3 is a promising novel biomarker of vascular inflammation and CAD which could potentially be used in early diagnosis of CAD and help determine the severity coronary atherosclerosis.
DISCLOSURE: The following authors have nothing to disclose: Pradyumna Agasthi, Sivakanth Aloor, Vivek Menon, Avantika Chenna , Anekwe Onwuanyi
No Product/Research Disclosure Information